Acumen reports Q3 net loss $13M, plans Phase 2 AD trial H1 2024, secures $50M credit facility

Acumen Pharmaceuticals, Inc.

2023-Q3 EPS reported -$0.79

Phase 2 ALTITUDE-AD trial expected to initiate H1 2024 after positive FDA feedback on study design.
CSF biomarkers p-tau181 (p=0.049) and neurogranin (p=0.037) significantly improved at 60 mg/kg dose in Phase 1.
Credit facility up to $50M from K2 HealthVentures; $30M drawn at closing, matures Nov 2027 or 2028 upon milestones.
Cash and equivalents $282.7M as of Sept 30, 2023; expected to fund operations into H2 2026.
Net loss $13.0M for Q3 2023 vs $10.7M Q3 2022; R&D spend $11.2M vs $8.3M YoY.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acumen Pharmaceuticals, Inc. reported financial results for Q3 2023.

Period: Q3 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended September 30, 2023.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001576885-23-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.